In the most recent issue of Genome Biology, Marco Marra and his colleagues use massively parallel sequencing to "characterize an adenocarcinoma of the tongue, before and after treatment" with sunitinib, sorafenib, and sulindac.
In the most recent issue of Genome Biology, Marco Marra and his colleagues use massively parallel sequencing to "characterize an adenocarcinoma of the tongue, before and after treatment" with sunitinib, sorafenib, and sulindac.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.